All In Biotech

Free tool

FAERS Monitor: Metaxalone

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022503 or its brand name (Metaxalone, Metaxalone). Reports on generic versions are filed under their own applications.

Reports

3,351

Serious

2,080

62% of reports

Hospitalization

793

Death reported

605

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • completed suicide261
  • drug ineffective208
  • pain201
  • nausea199
  • fatigue198
  • headache172
  • toxicity to various agents164
  • fall159
  • diarrhoea135
  • dizziness123
  • dyspnoea122
  • death117
  • vomiting113
  • chronic kidney disease111
  • renal failure107

Reports by year received

View as table
YearReports
200429
200546
200623
200728
200871
200923
201048
201175
2012105
2013172
2014159
2015283
2016322
2017240
2018270
2019366
2020342
2021179
2022153
202396
2024107
2025135
202679

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,808 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
completed suicideSignal26119.717.54,623
chronic kidney diseaseSignal1119.27.6803
toxicity to various agentsSignal1646.15.3701
renal failureSignal1075.14.2346
fallSignal1593.02.6213
painSignal2012.11.8111
headache1721.71.553
fatigue1981.61.445
nausea1991.61.443
dizziness1231.51.324
vomiting1131.51.319
dyspnoea1221.41.111
diarrhoea1351.31.110
drug ineffective2081.00.90
death1170.90.73

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.